UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 23, 2022

Palatin Technologies, Inc.

(Exact name of registrant as specified in its charter)

	Delaware	001-15543	95-4078884	
	(State or other jurisdiction	(Commission	(IRS employer	
	of incorporation)	File Number)	identification number)	
	4B Cedar Brook Drive, Cra	nbury, NJ	08512	
(Address of principal executive of		re offices)	(Zip Code)	
	Registrant's telepl	none number, including area cod	e: (609) 495-2200	
		Not Applicable		
	(Former name	e or former address, if changed sir	nce last report.)	
	eck the appropriate box below if the I registrant under any of the following	_	nultaneously satisfy the filing obligation of on A.2. below):	
		14a-12 under the Exchange Act (1 ns pursuant to Rule 14d-2(b) und		
Sec	curities registered pursuant to Section	12(b) of the Act:		
	Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered	
(Common Stock, par value \$0.01 per share	PTN	NYSE American	

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

			_
-merging	growth	company	

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Item 8.01 Other Events.

Extension of Agreement with Lonza Ltd.

The agreement (the "Lonza Agreement") of Palatin Technologies, Inc. (the "Company") with Lonza Ltd. ("Lonza") to manufacturer the Vyleesi® active drug ingredient was set to expire December 31, 2022. The Company engaged in discussions with Lonza and, on November 23, 2022, the Company and Lonza agreed to extend the term of the Lonza Agreement until June 30, 2024.

Redemption of Preferred Stock

As previously disclosed, on May 11, 2022, the Company entered into a Securities Purchase Agreement with Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P. (collectively, "Pontifax"), pursuant to which the Company agreed to issue and sell, in a private placement (the "Offering"), 8,100,000 shares of the Company's Series B Convertible Redeemable Preferred Stock, par value \$0.01 per share (the "Series B Convertible Preferred Stock"), and 900,000 shares of the Company's Series C Convertible Redeemable Preferred Stock, par value \$0.01 per share (together with Series B Convertible Preferred Stock, the "Preferred Stock"), for an aggregate offering price of \$15,000,000. Pursuant to an escrow agreement between the Company and Pontifax, the proceeds of the Offering as well as an additional \$750,000 contributed by the Company, were held in an escrow account (the "Escrow Account"). The Preferred Stock was redeemable at the option of Pontifax either in cash or in notes.

On November 23, 2022, Pontifax provided the Company with Notices of Redemption, stating that Pontifax elected to have the Preferred Stock redeemed in cash. Accordingly, the Company and Pontifax directed the escrow agent for the Escrow Account to release \$15,750,000 to Pontifax. On November 25, 2022, the funds were released from the Escrow Account and the Preferred Stock was redeemed in full.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PALATIN TECHNOLOGIES, INC.

Date: November 30, 2022

By:/s/ Stephen T. Wills

Stephen T. Wills, CPA, MST Executive Vice President, Chief Financial Officer and Chief Operating Officer